Restoration of risk-propensity during sleep deprivation: Caffeine, dextroamphetamine, and modafinil

William Killgore, Nancy L. Grugle, Desiree B. Killgore, Brian P. Leavitt, George I. Watlington, Shanelle McNair, Thomas J. Balkin

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Introduction: Sleep deprivation alters risk-related judgments, decision-making, and behavioral control. Stimulant medications are used to restore cognitive performance, but their effects on risk-taking and judgment in sleep-deprived subjects have not been explored. Methods: There were 54 healthy adults (29 men, 25 women; age range 18 to 36) who completed a test of cognitive ability and daily measures of risk-taking propensity, including the Brief Sensation Seeking Scale (BSSS), Evaluation of Risks (EVAR) scale, and the Balloon Analog Risk Task (BART). Following 44 h of continuous wakefulness, participants ingested caffeine 600 mg (N = 12), dextroamphetamine 20 mg (N = 16), modafinil 400 mg (N = 12), or a placebo (N = 14) in a double blind manner, and completed risk-taking measures 2 h later (i.e., 0535). Results: Relative to rested baseline, the placebo group showed a decline in risk-taking as measured by the BSSS (16% decline), EVAR Danger Seeking (32% decline) and Energy (22% decline), and BART (32% decline), consistent with previous reports of the effects of sleep deprivation. Comparisons among drug conditions showed that dextroamphetamine restored risk-taking propensity and risky behavior to baseline levels, an effect that was significantly greater than placebo or caffeine for several indices of risk-taking, but which did not differ from modafinil. Cognitive ability was significantly correlated with changes on some risk-taking indices following stimulant administration. Conclusions: Stimulant medications, particularly dextroamphetamine, sustained risk-related attitudes and behavior during continuous wakefulness. The extent to which stimulants restore other aspects of judgment during sleep loss remains to be determined.

Original languageEnglish (US)
Pages (from-to)867-874
Number of pages8
JournalAviation Space and Environmental Medicine
Volume79
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Caffeine
Dextroamphetamine
Sleep Deprivation
Risk-Taking
Restoration
Aptitude
Wakefulness
Placebos
Sleep
Balloons
modafinil
Decision Making
Pharmaceutical Preparations

Keywords

  • Caffeine
  • Dextroamphetamine
  • Modafinil
  • Risk
  • Sleep deprivation
  • Stimulants

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pollution
  • Medicine(all)

Cite this

Restoration of risk-propensity during sleep deprivation : Caffeine, dextroamphetamine, and modafinil. / Killgore, William; Grugle, Nancy L.; Killgore, Desiree B.; Leavitt, Brian P.; Watlington, George I.; McNair, Shanelle; Balkin, Thomas J.

In: Aviation Space and Environmental Medicine, Vol. 79, No. 9, 09.2008, p. 867-874.

Research output: Contribution to journalArticle

Killgore, William ; Grugle, Nancy L. ; Killgore, Desiree B. ; Leavitt, Brian P. ; Watlington, George I. ; McNair, Shanelle ; Balkin, Thomas J. / Restoration of risk-propensity during sleep deprivation : Caffeine, dextroamphetamine, and modafinil. In: Aviation Space and Environmental Medicine. 2008 ; Vol. 79, No. 9. pp. 867-874.
@article{718e035fa4a24dec99a59942d59f7909,
title = "Restoration of risk-propensity during sleep deprivation: Caffeine, dextroamphetamine, and modafinil",
abstract = "Introduction: Sleep deprivation alters risk-related judgments, decision-making, and behavioral control. Stimulant medications are used to restore cognitive performance, but their effects on risk-taking and judgment in sleep-deprived subjects have not been explored. Methods: There were 54 healthy adults (29 men, 25 women; age range 18 to 36) who completed a test of cognitive ability and daily measures of risk-taking propensity, including the Brief Sensation Seeking Scale (BSSS), Evaluation of Risks (EVAR) scale, and the Balloon Analog Risk Task (BART). Following 44 h of continuous wakefulness, participants ingested caffeine 600 mg (N = 12), dextroamphetamine 20 mg (N = 16), modafinil 400 mg (N = 12), or a placebo (N = 14) in a double blind manner, and completed risk-taking measures 2 h later (i.e., 0535). Results: Relative to rested baseline, the placebo group showed a decline in risk-taking as measured by the BSSS (16{\%} decline), EVAR Danger Seeking (32{\%} decline) and Energy (22{\%} decline), and BART (32{\%} decline), consistent with previous reports of the effects of sleep deprivation. Comparisons among drug conditions showed that dextroamphetamine restored risk-taking propensity and risky behavior to baseline levels, an effect that was significantly greater than placebo or caffeine for several indices of risk-taking, but which did not differ from modafinil. Cognitive ability was significantly correlated with changes on some risk-taking indices following stimulant administration. Conclusions: Stimulant medications, particularly dextroamphetamine, sustained risk-related attitudes and behavior during continuous wakefulness. The extent to which stimulants restore other aspects of judgment during sleep loss remains to be determined.",
keywords = "Caffeine, Dextroamphetamine, Modafinil, Risk, Sleep deprivation, Stimulants",
author = "William Killgore and Grugle, {Nancy L.} and Killgore, {Desiree B.} and Leavitt, {Brian P.} and Watlington, {George I.} and Shanelle McNair and Balkin, {Thomas J.}",
year = "2008",
month = "9",
doi = "10.3357/ASEM.2259.2008",
language = "English (US)",
volume = "79",
pages = "867--874",
journal = "Aerospace medicine and human performance",
issn = "2375-6314",
publisher = "Aerospace Medical Association",
number = "9",

}

TY - JOUR

T1 - Restoration of risk-propensity during sleep deprivation

T2 - Caffeine, dextroamphetamine, and modafinil

AU - Killgore, William

AU - Grugle, Nancy L.

AU - Killgore, Desiree B.

AU - Leavitt, Brian P.

AU - Watlington, George I.

AU - McNair, Shanelle

AU - Balkin, Thomas J.

PY - 2008/9

Y1 - 2008/9

N2 - Introduction: Sleep deprivation alters risk-related judgments, decision-making, and behavioral control. Stimulant medications are used to restore cognitive performance, but their effects on risk-taking and judgment in sleep-deprived subjects have not been explored. Methods: There were 54 healthy adults (29 men, 25 women; age range 18 to 36) who completed a test of cognitive ability and daily measures of risk-taking propensity, including the Brief Sensation Seeking Scale (BSSS), Evaluation of Risks (EVAR) scale, and the Balloon Analog Risk Task (BART). Following 44 h of continuous wakefulness, participants ingested caffeine 600 mg (N = 12), dextroamphetamine 20 mg (N = 16), modafinil 400 mg (N = 12), or a placebo (N = 14) in a double blind manner, and completed risk-taking measures 2 h later (i.e., 0535). Results: Relative to rested baseline, the placebo group showed a decline in risk-taking as measured by the BSSS (16% decline), EVAR Danger Seeking (32% decline) and Energy (22% decline), and BART (32% decline), consistent with previous reports of the effects of sleep deprivation. Comparisons among drug conditions showed that dextroamphetamine restored risk-taking propensity and risky behavior to baseline levels, an effect that was significantly greater than placebo or caffeine for several indices of risk-taking, but which did not differ from modafinil. Cognitive ability was significantly correlated with changes on some risk-taking indices following stimulant administration. Conclusions: Stimulant medications, particularly dextroamphetamine, sustained risk-related attitudes and behavior during continuous wakefulness. The extent to which stimulants restore other aspects of judgment during sleep loss remains to be determined.

AB - Introduction: Sleep deprivation alters risk-related judgments, decision-making, and behavioral control. Stimulant medications are used to restore cognitive performance, but their effects on risk-taking and judgment in sleep-deprived subjects have not been explored. Methods: There were 54 healthy adults (29 men, 25 women; age range 18 to 36) who completed a test of cognitive ability and daily measures of risk-taking propensity, including the Brief Sensation Seeking Scale (BSSS), Evaluation of Risks (EVAR) scale, and the Balloon Analog Risk Task (BART). Following 44 h of continuous wakefulness, participants ingested caffeine 600 mg (N = 12), dextroamphetamine 20 mg (N = 16), modafinil 400 mg (N = 12), or a placebo (N = 14) in a double blind manner, and completed risk-taking measures 2 h later (i.e., 0535). Results: Relative to rested baseline, the placebo group showed a decline in risk-taking as measured by the BSSS (16% decline), EVAR Danger Seeking (32% decline) and Energy (22% decline), and BART (32% decline), consistent with previous reports of the effects of sleep deprivation. Comparisons among drug conditions showed that dextroamphetamine restored risk-taking propensity and risky behavior to baseline levels, an effect that was significantly greater than placebo or caffeine for several indices of risk-taking, but which did not differ from modafinil. Cognitive ability was significantly correlated with changes on some risk-taking indices following stimulant administration. Conclusions: Stimulant medications, particularly dextroamphetamine, sustained risk-related attitudes and behavior during continuous wakefulness. The extent to which stimulants restore other aspects of judgment during sleep loss remains to be determined.

KW - Caffeine

KW - Dextroamphetamine

KW - Modafinil

KW - Risk

KW - Sleep deprivation

KW - Stimulants

UR - http://www.scopus.com/inward/record.url?scp=51149117077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51149117077&partnerID=8YFLogxK

U2 - 10.3357/ASEM.2259.2008

DO - 10.3357/ASEM.2259.2008

M3 - Article

C2 - 18785355

AN - SCOPUS:51149117077

VL - 79

SP - 867

EP - 874

JO - Aerospace medicine and human performance

JF - Aerospace medicine and human performance

SN - 2375-6314

IS - 9

ER -